Search results
Results from the WOW.Com Content Network
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Mosunetuzumab-axgb was evaluated in GO29781 (NCT02500407), an open-label, multicenter, multi-cohort study. [3] The efficacy population consisted of 90 patients with relapsed or refractory FL who had received at least two prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. [18] The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. [24] In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6]
She was recruited to Genentech in 2006, and in 2018 was promoted to Senior Vice President of Small Molecule drug discovery. [1] One of her major research successes was development of a chemistry campaign against Bruton's tyrosine kinase, leading to molecules to potentially treat rheumatoid arthritis and B-cell lymphomas. [8]
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. [9] The FDA granted the approval of Polivy to Genentech. [9] Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. [7]